BARCELONA--(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the most common cancer in Europe, and the third most common cancer worldwide. Each year, 138,000 Europeans die from the disease. However, colorectal cancer is preventable in most cases and highly treatable if diagnosed in its early stages.